Content reviewed by clinical research staff

Last reviewed: March 2026Sources: PubMed, FDA, WADA Prohibited List

Evidence graded using the PeptideScholar A-D system.

Semax

Synthetic ACTH(4-10) analog7 amino acids

BHuman Studies
80
Good Credibility
2 cited studies | Evidence level B

Semax is a synthetic peptide derived from the ACTH(4-10) fragment, developed in Russia as a nootropic and neuroprotective agent. It is approved in Russia for stroke, cognitive disorders, and optic nerve disease.

Mechanism of Action

Enhances BDNF and NGF expression. Modulates dopaminergic, serotonergic, and cholinergic neurotransmission. Increases cerebral blood flow and has anti-inflammatory effects in the CNS.

Benefits

  • Neuroprotective effects in stroke (Russian clinical trials)[1]
  • Enhanced memory and cognitive performance[1]
  • Approved in Russia for multiple neurological conditions[1]
  • No hormonal effects despite ACTH origin[1]
Not medical advice - research-reported information only

This content is for informational purposes only and does not constitute medical advice.

Semax - Dosing in Published Research

Reported routes: Intranasal, Subcutaneous injection
Russian approved dosing: 200-600 mcg intranasal daily. Higher doses (up to 1.2 mg) used for acute stroke treatment.

The dosing information above is sourced from published research literature and clinical trials. These are not recommendations. Individual responses vary. Always consult a healthcare provider before considering any peptide-based therapy.

Side Effects

  • Well-tolerated in Russian clinical use[1]
  • Mild headache rarely[1]
  • Nasal irritation with intranasal use[1]
  • Limited Western safety data[1]

Considering peptide research?

Semax is not FDA-approved. Always consult a licensed healthcare provider before considering any peptide.

Use the Peptide Finder

Use the guided tool to narrow the safest next step.

Always consult a professional

Research & Evidence

Compare Semax With

References

  1. 1.[Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)].. Zh Nevrol Psikhiatr Im S S Korsakova, 1997. "Semax improved neurological outcomes and reduced disability when administered within 12 hours of ischemic stroke onset" [PMID: 11517472]
  2. 2.The heptapeptide SEMAX stimulates BDNF expression in different areas of the rat brain in vivo.. Dokl Biol Sci, 2003. "Semax upregulated BDNF and NGF expression in rat brain, supporting its neuroprotective mechanism" [PMID: 14556513]

Recommended Resources

The Peptide Protocols Handbook

Evidence-based reference guide covering mechanisms, research, and clinical applications.

View on Amazon

Third-Party Peptide Testing

Independent lab analysis to verify peptide purity and authenticity.

Learn More

Links may be affiliate links. See our disclosure.

Research Supplies

Equipment for responsible research-grade peptide handling and administration.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Recommended Reading

Books covering peptide science, longevity research, and biohacking frameworks.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.